C
GSK plc
GLAXF
$20.00
$0.653.36%
C
Hold
10/31/2024Downgrade
GSK plc (GLAXF) was downgraded to C- from C on 10/31/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.3595 to -$0.0185, net income declined 105.1% from $1.48B to -$75.48M, and EBIT declined 68.94% from $2.79B to $867.97M.
GSK plc (GLAXF) was downgraded to C- from C on 10/31/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.3595 to -$0.0185, net income declined 105.1% from $1.48B to -$75.48M, and EBIT declined 68.94% from $2.79B to $867.97M.
C
Hold
10/18/2023Upgraded
GSK plc (GLAXF) was upgraded to C from C- on 10/18/2023 due to an increase in the total return index.
GSK plc (GLAXF) was upgraded to C from C- on 10/18/2023 due to an increase in the total return index.
C
Hold
10/3/2023Downgrade
GSK plc (GLAXF) was downgraded to C- from C on 10/3/2023 due to a decline in the volatility index, valuation index and dividend index.
GSK plc (GLAXF) was downgraded to C- from C on 10/3/2023 due to a decline in the volatility index, valuation index and dividend index.
C
Hold
9/18/2023Upgraded
GSK plc (GLAXF) was upgraded to C from C- on 9/18/2023 due to an increase in the volatility index and total return index.
GSK plc (GLAXF) was upgraded to C from C- on 9/18/2023 due to an increase in the volatility index and total return index.
C
Hold
8/15/2023Downgrade
GSK plc (GLAXF) was downgraded to C- from C on 8/15/2023 due to a noticeable decline in the growth index and volatility index.
GSK plc (GLAXF) was downgraded to C- from C on 8/15/2023 due to a noticeable decline in the growth index and volatility index.
C
Hold
4/17/2023Upgraded
GSK plc (GLAXF) was upgraded to C from C- on 4/17/2023 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 2.55 to 1.85.
GSK plc (GLAXF) was upgraded to C from C- on 4/17/2023 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 2.55 to 1.85.
C
Hold
12/20/2022Upgraded
GSK plc (GLAXF) was upgraded to C- from D+ on 12/20/2022 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.2595 to $2.9711, EBIT increased 29.43% from $2.15B to $2.78B, and total revenue increased 5.86% from $8.71B to $9.22B.
GSK plc (GLAXF) was upgraded to C- from D+ on 12/20/2022 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from $0.2595 to $2.9711, EBIT increased 29.43% from $2.15B to $2.78B, and total revenue increased 5.86% from $8.71B to $9.22B.
D
Sell
11/2/2022Downgrade
GSK plc (GLAXF) was downgraded to D+ from C- on 11/2/2022 due to a decline in the total return index and volatility index.
GSK plc (GLAXF) was downgraded to D+ from C- on 11/2/2022 due to a decline in the total return index and volatility index.
C
Hold
8/30/2022Downgrade
GSK plc (GLAXF) was downgraded to C- from C on 8/30/2022 due to a noticeable decline in the total return index and volatility index.
GSK plc (GLAXF) was downgraded to C- from C on 8/30/2022 due to a noticeable decline in the total return index and volatility index.
C
Hold
8/9/2022Downgrade
GSK plc (GLAXD) was downgraded to C from C+ on 8/9/2022 due to a significant decline in the growth index, total return index and solvency index. The quick ratio declined from 0.94 to 0.35, earnings per share declined from $0.5962 to $0.2595, and total revenue declined 9.64% from $9.64B to $8.71B.
GSK plc (GLAXD) was downgraded to C from C+ on 8/9/2022 due to a significant decline in the growth index, total return index and solvency index. The quick ratio declined from 0.94 to 0.35, earnings per share declined from $0.5962 to $0.2595, and total revenue declined 9.64% from $9.64B to $8.71B.
C
Hold
7/19/2022Downgrade
GSK plc (GLAXF) was downgraded to C+ from B- on 7/19/2022 due to a decline in the volatility index and total return index.
GSK plc (GLAXF) was downgraded to C+ from B- on 7/19/2022 due to a decline in the volatility index and total return index.
B
Buy
7/18/2022Downgrade
GSK plc (GLAXF) was downgraded to B- from B on 7/18/2022 due to a decline in the total return index and volatility index.
GSK plc (GLAXF) was downgraded to B- from B on 7/18/2022 due to a decline in the total return index and volatility index.
B
Buy
5/20/2022Upgraded
GSK plc (GLAXF) was upgraded to B from C on 5/20/2022 due to an increase in the valuation index, volatility index and dividend index.
GSK plc (GLAXF) was upgraded to B from C on 5/20/2022 due to an increase in the valuation index, volatility index and dividend index.
C
Hold
5/4/2022Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from B on 5/4/2022 due to a decline in the volatility index.
GlaxoSmithKline plc (GLAXF) was downgraded to C from B on 5/4/2022 due to a decline in the volatility index.
B
Buy
5/3/2022Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 5/3/2022 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from $0.1998 to $0.4773, the quick ratio increased from 0.52 to 0.94, and EBIT increased 33.27% from $2.28B to $3.04B.
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 5/3/2022 due to a significant increase in the growth index, total return index and solvency index. Earnings per share increased from $0.1998 to $0.4773, the quick ratio increased from 0.52 to 0.94, and EBIT increased 33.27% from $2.28B to $3.04B.
B
Buy
3/15/2022Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C on 3/15/2022 due to an increase in the valuation index, efficiency index and dividend index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C on 3/15/2022 due to an increase in the valuation index, efficiency index and dividend index.
C
Hold
2/25/2022Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from B on 2/25/2022 due to a decline in the volatility index.
GlaxoSmithKline plc (GLAXF) was downgraded to C from B on 2/25/2022 due to a decline in the volatility index.
B
Buy
2/23/2022Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 2/23/2022 due to an increase in the total return index, volatility index and growth index.
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 2/23/2022 due to an increase in the total return index, volatility index and growth index.
B
Buy
12/1/2021Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 12/1/2021 due to a decline in the volatility index.
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 12/1/2021 due to a decline in the volatility index.
B
Buy
11/16/2021Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 11/16/2021 due to an increase in the total return index and volatility index.
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 11/16/2021 due to an increase in the total return index and volatility index.
B
Buy
11/3/2021Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C on 11/3/2021 due to a noticeable increase in the total return index, dividend index and growth index. Operating cash flow increased 95.43% from $1.81B to $3.53B, EBIT increased 32.37% from $2.77B to $3.66B, and total revenue increased 10.55% from $11.31B to $12.51B.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C on 11/3/2021 due to a noticeable increase in the total return index, dividend index and growth index. Operating cash flow increased 95.43% from $1.81B to $3.53B, EBIT increased 32.37% from $2.77B to $3.66B, and total revenue increased 10.55% from $11.31B to $12.51B.
C
Hold
10/1/2021Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 10/1/2021 due to a decline in the volatility index and total return index.
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 10/1/2021 due to a decline in the volatility index and total return index.
C
Hold
9/16/2021Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 9/16/2021 due to an increase in the volatility index and total return index.
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 9/16/2021 due to an increase in the volatility index and total return index.
C
Hold
7/29/2021Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 7/29/2021 due to a decline in the valuation index, dividend index and efficiency index.
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 7/29/2021 due to a decline in the valuation index, dividend index and efficiency index.
C
Hold
7/20/2021Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 7/20/2021 due to an increase in the efficiency index, volatility index and solvency index. Net income increased 65.64% from $893.56M to $1.48B.
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 7/20/2021 due to an increase in the efficiency index, volatility index and solvency index. Net income increased 65.64% from $893.56M to $1.48B.
C
Hold
8/18/2020Downgrade
GSK plc (GLAXF) was downgraded to C from B- on 08/18/2020.
GSK plc (GLAXF) was downgraded to C from B- on 08/18/2020.
B
Buy
8/14/2020Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 8/14/2020 due to an increase in the dividend index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 8/14/2020 due to an increase in the dividend index.
C
Hold
7/30/2020Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/30/2020 due to a decline in the dividend index.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/30/2020 due to a decline in the dividend index.
B
Buy
7/17/2020Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 7/17/2020 due to an increase in the volatility index, total return index and valuation index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 7/17/2020 due to an increase in the volatility index, total return index and valuation index.
C
Hold
6/30/2020Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 6/30/2020 due to an increase in the dividend index and valuation index.
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 6/30/2020 due to an increase in the dividend index and valuation index.
C
Hold
5/5/2020Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 5/5/2020 due to a large decline in the growth index, dividend index and total return index. Operating cash flow declined 72.22% from $4.44B to $1.23B, and EBIT declined 7.88% from $2.8B to $2.58B.
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 5/5/2020 due to a large decline in the growth index, dividend index and total return index. Operating cash flow declined 72.22% from $4.44B to $1.23B, and EBIT declined 7.88% from $2.8B to $2.58B.
C
Hold
4/29/2020Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 4/29/2020 due to a decline in the valuation index, volatility index and dividend index.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 4/29/2020 due to a decline in the valuation index, volatility index and dividend index.
B
Buy
4/14/2020Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 4/14/2020 due to an increase in the volatility index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 4/14/2020 due to an increase in the volatility index.
C
Hold
4/9/2020Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 4/9/2020 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 43.35% from $3.1B to $4.44B.
GlaxoSmithKline plc (GLAXF) was upgraded to C+ from C on 4/9/2020 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 43.35% from $3.1B to $4.44B.
C
Hold
5/11/2018Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 5/11/2018 due to an increase in the dividend index, volatility index and valuation index.
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 5/11/2018 due to an increase in the dividend index, volatility index and valuation index.
C
Hold
4/26/2018Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 4/26/2018 due to a substantial decline in the valuation index, dividend index and efficiency index.
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 4/26/2018 due to a substantial decline in the valuation index, dividend index and efficiency index.
C
Hold
4/3/2018Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 4/3/2018 due to an increase in the total return index.
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 4/3/2018 due to an increase in the total return index.
C
Hold
3/19/2018Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 3/19/2018 due to a noticeable decline in the volatility index and total return index.
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 3/19/2018 due to a noticeable decline in the volatility index and total return index.
C
Hold
9/1/2017Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 9/1/2017 due to an increase in the dividend index, growth index and valuation index.
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 9/1/2017 due to an increase in the dividend index, growth index and valuation index.
C
Hold
7/27/2017Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 7/27/2017 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from $0.264 to -$0.0474, debt to equity increased from 10.59 to 22.93, and EBIT declined 101.11% from $2.3B to -$25.6M.
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 7/27/2017 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from $0.264 to -$0.0474, debt to equity increased from 10.59 to 22.93, and EBIT declined 101.11% from $2.3B to -$25.6M.
C
Hold
4/27/2017Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 4/27/2017 due to a major increase in the valuation index, growth index and solvency index. EBIT increased 732.13% from $255.86M to $2.13B, earnings per share increased from $0.065 to $0.264, and debt to equity declined from 16.78 to 10.59.
GlaxoSmithKline plc (GLAXF) was upgraded to C from C- on 4/27/2017 due to a major increase in the valuation index, growth index and solvency index. EBIT increased 732.13% from $255.86M to $2.13B, earnings per share increased from $0.065 to $0.264, and debt to equity declined from 16.78 to 10.59.
C
Hold
3/31/2017Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 3/31/2017 due to an increase in the total return index and volatility index.
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 3/31/2017 due to an increase in the total return index and volatility index.
D
Sell
3/16/2017Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 3/16/2017 due to a noticeable decline in the growth index and efficiency index. EBIT declined 90.9% from $2.81B to $255.76M, earnings per share declined from $0.2166 to $0.065, and net income declined 69.92% from $1.06B to $319.07M.
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 3/16/2017 due to a noticeable decline in the growth index and efficiency index. EBIT declined 90.9% from $2.81B to $255.76M, earnings per share declined from $0.2166 to $0.065, and net income declined 69.92% from $1.06B to $319.07M.
C
Hold
3/10/2017Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 3/10/2017 due to an increase in the total return index.
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 3/10/2017 due to an increase in the total return index.
D
Sell
1/19/2017Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 1/19/2017 due to a noticeable decline in the volatility index, solvency index and total return index. Debt to equity increased from 36.82 to 141.43.
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 1/19/2017 due to a noticeable decline in the volatility index, solvency index and total return index. Debt to equity increased from 36.82 to 141.43.
C
Hold
8/12/2016Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 8/12/2016 due to an increase in the efficiency index, dividend index and growth index.
GlaxoSmithKline plc (GLAXF) was upgraded to C- from D+ on 8/12/2016 due to an increase in the efficiency index, dividend index and growth index.
D
Sell
7/28/2016Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 7/28/2016 due to a substantial decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 6.01 to 36.82, net income declined 254.68% from $403.46M to -$624.06M, and the quick ratio declined from 0.75 to 0.59.
GlaxoSmithKline plc (GLAXF) was downgraded to D+ from C- on 7/28/2016 due to a substantial decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 6.01 to 36.82, net income declined 254.68% from $403.46M to -$624.06M, and the quick ratio declined from 0.75 to 0.59.
C
Hold
4/28/2016Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 4/28/2016 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.34 to 6.01, operating cash flow declined 68.4% from $2.28B to $719.65M, and the quick ratio declined from 0.86 to 0.75.
GlaxoSmithKline plc (GLAXF) was downgraded to C- from C on 4/28/2016 due to a significant decline in the valuation index, growth index and solvency index. Debt to equity increased from 3.34 to 6.01, operating cash flow declined 68.4% from $2.28B to $719.65M, and the quick ratio declined from 0.86 to 0.75.
C
Hold
3/11/2016Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 3/11/2016 due to a large decline in the volatility index and total return index.
GlaxoSmithKline plc (GLAXF) was downgraded to C from C+ on 3/11/2016 due to a large decline in the volatility index and total return index.
C
Hold
2/22/2016Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 2/22/2016 due to a decline in the total return index.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 2/22/2016 due to a decline in the total return index.
B
Buy
1/15/2016Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 1/15/2016 due to a large decline in the total return index and volatility index.
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 1/15/2016 due to a large decline in the total return index and volatility index.
B
Buy
12/31/2015Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 12/31/2015 due to a noticeable increase in the total return index and valuation index.
GlaxoSmithKline plc (GLAXF) was upgraded to B from B- on 12/31/2015 due to a noticeable increase in the total return index and valuation index.
B
Buy
11/13/2015Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 11/13/2015 due to a noticeable increase in the growth index, dividend index and total return index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 11/13/2015 due to a noticeable increase in the growth index, dividend index and total return index.
C
Hold
10/29/2015Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 10/29/2015 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 2.45 to 3.12, and the quick ratio declined from 0.94 to 0.94.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 10/29/2015 due to a decline in the dividend index, solvency index and total return index. Debt to equity increased from 2.45 to 3.12, and the quick ratio declined from 0.94 to 0.94.
B
Buy
8/14/2015Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 8/14/2015 due to an increase in the dividend index, growth index and total return index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 8/14/2015 due to an increase in the dividend index, growth index and total return index.
C
Hold
7/30/2015Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/30/2015 due to a decline in the dividend index, solvency index and growth index. Earnings per share declined from $5.0368 to $0.0946, EBIT declined 68.25% from $1.62B to $513.68M, and operating cash flow declined 40.58% from $559.98M to $332.74M.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/30/2015 due to a decline in the dividend index, solvency index and growth index. Earnings per share declined from $5.0368 to $0.0946, EBIT declined 68.25% from $1.62B to $513.68M, and operating cash flow declined 40.58% from $559.98M to $332.74M.
B
Buy
7/23/2015Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 7/23/2015 due to an increase in the volatility index.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 7/23/2015 due to an increase in the volatility index.
C
Hold
7/7/2015Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/7/2015 due to a decline in the total return index, volatility index and growth index.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 7/7/2015 due to a decline in the total return index, volatility index and growth index.
B
Buy
5/7/2015Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 5/7/2015 due to a significant increase in the valuation index, solvency index and growth index. Earnings per share increased from $0.337 to $2.5184, EBIT increased 448.8% from $2.54B to $13.95B, and the quick ratio increased from 0.67 to 1.01.
GlaxoSmithKline plc (GLAXF) was upgraded to B- from C+ on 5/7/2015 due to a significant increase in the valuation index, solvency index and growth index. Earnings per share increased from $0.337 to $2.5184, EBIT increased 448.8% from $2.54B to $13.95B, and the quick ratio increased from 0.67 to 1.01.
C
Hold
3/2/2015Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 3/2/2015 due to a substantial decline in the growth index, valuation index and solvency index. Debt to equity increased from 3.87 to 4.46.
GlaxoSmithKline plc (GLAXF) was downgraded to C+ from B- on 3/2/2015 due to a substantial decline in the growth index, valuation index and solvency index. Debt to equity increased from 3.87 to 4.46.
B
Buy
10/7/2014Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 10/7/2014 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.77 to 0.68, and debt to equity increased from 2.59 to 2.84.
GlaxoSmithKline plc (GLAXF) was downgraded to B- from B on 10/7/2014 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.77 to 0.68, and debt to equity increased from 2.59 to 2.84.
B
Buy
7/23/2014Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B from B+ on 7/23/2014 due to a decline in the volatility index and total return index.
GlaxoSmithKline plc (GLAXF) was downgraded to B from B+ on 7/23/2014 due to a decline in the volatility index and total return index.
B
Buy
6/20/2014Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to B+ from B on 6/20/2014 due to an increase in the volatility index.
GlaxoSmithKline plc (GLAXF) was upgraded to B+ from B on 6/20/2014 due to an increase in the volatility index.
B
Buy
6/5/2014Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B from B+ on 6/5/2014 due to a decline in the total return index, volatility index and solvency index.
GlaxoSmithKline plc (GLAXF) was downgraded to B from B+ on 6/5/2014 due to a decline in the total return index, volatility index and solvency index.
B
Buy
5/2/2014Downgrade
GlaxoSmithKline plc (GLAXF) was downgraded to B+ from A- on 5/2/2014 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.8167 to $0.2267, operating cash flow declined 56.66% from $3.54B to $1.53B, and EBIT declined 43.16% from $3.52B to $2B.
GlaxoSmithKline plc (GLAXF) was downgraded to B+ from A- on 5/2/2014 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.8167 to $0.2267, operating cash flow declined 56.66% from $3.54B to $1.53B, and EBIT declined 43.16% from $3.52B to $2B.
A
Buy
3/3/2014Upgraded
GlaxoSmithKline plc (GLAXF) was upgraded to A- from B+ on 3/3/2014 due to a significant increase in growth, valuation and solvency. Earnings per share increased from $0.6112 to $1.6335, EBIT increased 25.7% from $2.8B to $3.52B, and the quick ratio increased from 0.67 to 0.8.
GlaxoSmithKline plc (GLAXF) was upgraded to A- from B+ on 3/3/2014 due to a significant increase in growth, valuation and solvency. Earnings per share increased from $0.6112 to $1.6335, EBIT increased 25.7% from $2.8B to $3.52B, and the quick ratio increased from 0.67 to 0.8.
OTC PK
03/10/2025 9:32AM Eastern
Quotes delayed
